An injectable Viscum album preparation Steiner introduced in 1917 and Ita Wegman developed clinically as a complementary cancer therapy at the Klinik Arlesheim.
Mistletoe (Iscador) in Anthroposophy is the cancer therapy Rudolf Steiner introduced in 1917 and Dr. Ita Wegman developed clinically at the Klinik Arlesheim from 1921. The preparation is an injectable extract of Viscum album fermented from paired summer and winter harvests, framed by Steiner as a substance whose lunar-epoch parasitic nature counter-images the etheric displacement he observed in tumor formation. The first commercial production began in 1917 under Iscador AG in Switzerland.
In Steiner's Own Words
Isn't it true that the absurdity also lies in the fact that the entire existence of mistletoe is dependent on the fact that the fertilization of mistletoe relies on transmission by bird flight in all these things; isn't it true that mistletoe would die out if the birds did not constantly carry the fertilizing substances from one tree to another? Curiously, these fertilizing substances also choose the path through the birds, so that the mistletoe substances are first absorbed into the birds' bodies and then emptied again, only to sprout again on another tree. These are all things that, when observed properly, allow us to see into the whole process of mistletoe formation, if I may say so.
What it Means Today
Anthroposophic medicine treats mistletoe therapy as a complementary intervention developed inside a specific clinical lineage, not as a stand-alone cure. Steiner gave the indications across the 1920 doctor's course (GA 312, Lectures 18 to 20). Ita Wegman opened the Klinik Arlesheim in Canton Basel-Country, Switzerland, in 1921 and refined the dosing, harvest timing, and administration protocols that became Iscador. The signature of the preparation is the seven-fold mixing of paired summer and winter extracts on a rotating centrifuge disc Steiner specified by hand, a methodology distinct from herbal tinctures and from homeopathic potentisation.
Today the preparation ships under several standardised brand names. Iscador AG remains the original Swiss manufacturer; Helixor Heilmittel GmbH in Rosenfeld and Abnoba GmbH in Pforzheim produce parallel German preparations; Iscucin (Wala) and Mistilis round out the European pharmacopeia. The substance is given by subcutaneous injection in an ascending dose series, host-tree-matched to the cancer site, alongside conventional oncological care. Clinical use is concentrated in Germany, Switzerland, Austria, and the Netherlands, with a peer-reviewed evidence base on quality of life and tumor-marker response that has accumulated since the year 2000 in journals such as European Journal of Cancer, Anticancer Research, and Integrative Cancer Therapies. The Thalira reading of Steiner's framework runs through GA 312 paired with the lunar-epoch passage in GA 94: mistletoe is the one plant whose biology never let go of an older Earth-state, and the therapy works by introducing that arrested rhythm against the etheric arrest Steiner saw in malignancy.
Where to Read More
This entry is a conceptual and historical definition of Steiner's framework. It is not medical advice. Mistletoe therapy is a regulated complementary medicine; any clinical use must be discussed with your oncologist and a licensed anthroposophic physician.